Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Baxter International, Inc. (BAX)

Core Viewpoint - A securities class action lawsuit has been filed against Baxter International, Inc. for allegedly misleading investors regarding the safety and efficacy of its Novum LVP devices, which reportedly suffered from systemic defects leading to serious patient risks [1][2]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Northern District of Illinois on behalf of all individuals or entities that purchased Baxter securities between February 23, 2022, and July 30, 2025 [1]. - The complaint alleges that Baxter failed to disclose significant issues with the Novum LVP, including systemic defects that caused malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids [2]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths related to these defects but did not take adequate remedial measures [2]. Group 2: Implications for Baxter - Due to the defects, there was an increased risk that customers would be instructed to take existing Novum LVPs out of service, and Baxter might have to halt all new sales of these pumps [2]. - The statements made by Baxter regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [2]. Group 3: Investor Actions - Investors who acquired shares of Baxter are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline on December 15, 2025 [3].